GRACE THERAPEUTICS INC
GRCENASDAQTrading Snapshot
- Day Range
- $1.69 β $1.74
- 52-Week Range
- $1.64 β $5.18
- Volume (shares)
- 767
- Avg Volume (shares)
- β
- Shares Outstanding
- 21.0M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 178.8x
- EPS (TTM)
- $-1.18
- Dividend Yield
- β
- Dilution (1yr)
- +18.8%
GRACE THERAPEUTICS INC
GRCEAbout GRACE THERAPEUTICS INC
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.